Fever News and Research

RSS

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Scientists find increases in rain and temperature could signal deadly cholera outbreaks months before they strike

With recent deadly cholera outbreaks in Haiti and Cameroon providing the latest indication of a menacingly resurgent disease, scientists have discovered rain and temperature fluctuations in at-risk areas could predict epidemics months in advance, according to a new study published today in the June 2011 issue of the American Journal of Tropical Medicine and Hygiene.

1 Jun 2011

Novartis employees to do volunteer work for non-profit groups during 15th annual Community Partnership Day

Some 200 employees of Novartis Pharmaceuticals Canada Inc. will again this year be helping out with cleaning, painting and various other chores and activities at 15 Montreal-area organizations as part of their 15th annual Community Partnership Day, during which they leave their offices for the day to do volunteer work for non-profit groups. It is part of a global effort by Novartis employees that involves 20,000 employees in 55 countries.

30 May 2011

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.

30 May 2011

WGO to focus on diarrheal disease prevention, management during World Digestive Health Day

Diarrheal disease, a common gastrointestinal problem with potentially fatal implications in the developing world is the focus of World Digestive Health Day on May 29. Infections that cause diarrhea are serious public health challenges, both in the United States and globally.

27 May 2011

Medicago, USAMRIID enter research collaboration for Ebola vaccine candidate

Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has entered into a research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for the development of a plant-based VLP vaccine candidate for the prevention of Ebola. Ebola is a very serious hemorrhagic fever virus for which no licensed treatment or vaccine exists.

26 May 2011

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

A widely used combination of two common medications may cause unexpected increases in blood glucose levels, according to a study conducted at the Stanford University School of Medicine, Vanderbilt University and Harvard Medical School. Researchers were surprised at the finding because neither of the two drugs - one, an antidepressant marketed as Paxil, and the other, a cholesterol-lowering medication called Pravachol - has a similar effect alone.

26 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Biogen Idec launches educational forum, 'Women in MS'

Biogen Idec today announced the launch of "Women in MS," an educational initiative to address both the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis.

25 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

First nucleic acid amplification test to diagnose early stages of Q fever infections receives FDA approval

The U.S. Food and Drug Administration today cleared the first nucleic acid amplification test to diagnose the early stages of Q fever infections in military personnel serving overseas.

21 May 2011

Most paediatric paracetamol prescriptions fails to comply with BNFc recommendations

Many of the prescriptions issued by GPs for paracetamol either give less than recommended doses to older children or exceed recommended doses in young children.

20 May 2011

Bitter cumin contains high levels of antioxidants and protects against DNA damage

Bitter cumin is used extensively in traditional medicine to treat a range of diseases from vitiligo to hyperglycemia. It is considered to be antiparasitic and antimicrobial and science has backed up claims of its use to reduce fever or as a painkiller. New research published in BioMedCentral's open access journal BMC Complementary and Alternative Medicine shows that this humble spice also contains high levels of antioxidants.

20 May 2011

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD Lipid study as they relate to the use of fenofibric acid (sold as Trilipix in the United States) in combination with a statin in patients with mixed dyslipidemia and at high risk of heart disease.

20 May 2011

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.

20 May 2011

Panel votes 20-0 for reformed labeling of kids’ pain & fever relieving medication

A federal advisory panel unanimously recommended that dosing for children's acetaminophen be based primarily on the child's weight rather than age. At present the dosing for children's products including acetaminophen- best known by the brand name Tylenol- is based on age, although many labels also contain information on dosing by weight as well. Acetaminophen is the most commonly used medicine meant to lower fever and relieve pain in children.

19 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Fever News and Research

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Scientists find increases in rain and temperature could signal deadly cholera outbreaks months before they strike

Novartis employees to do volunteer work for non-profit groups during 15th annual Community Partnership Day

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

WGO to focus on diarrheal disease prevention, management during World Digestive Health Day

Medicago, USAMRIID enter research collaboration for Ebola vaccine candidate

Paxil and Pravachol in combination cause unexpected increase in blood glucose levels

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Biogen Idec launches educational forum, 'Women in MS'

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Vertex receives FDA approval for INCIVEK to treat hepatitis C

First nucleic acid amplification test to diagnose early stages of Q fever infections receives FDA approval

Most paediatric paracetamol prescriptions fails to comply with BNFc recommendations

Bitter cumin contains high levels of antioxidants and protects against DNA damage

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

Panel votes 20-0 for reformed labeling of kids’ pain & fever relieving medication

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News